Literature DB >> 19783850

Use of inactivated bluetongue virus serotype 8 vaccine against virulent challenge in sheep and cattle.

C Hamers1, S Galleau, R Chery, M Blanchet, L Besancon, C Cariou, B Werle-Lapostolle, P Hudelet, S Goutebroze.   

Abstract

The immunisation properties of an inactivated bluetongue virus serotype 8 (BTV-8) vaccine were evaluated in sheep and cattle. Five sheep were vaccinated with one dose of vaccine and five cattle were vaccinated with two doses 28 days apart. Six sheep and five cattle served as unvaccinated controls. All animals were subjected to a virulent BTV-8 challenge, and safety and antibody responses were monitored. All control animals developed disease and viraemia, while vaccinated animals were clinically protected and viraemia was completely prevented.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19783850     DOI： 10.1136/vr.165.13.369

Source DB:  PubMed          Journal:  Vet Rec        ISSN： 0042-4900            Impact factor:   2.695


  10 in total

1.  The spread of bluetongue virus serotype 8 in Great Britain and its control by vaccination.

Authors:  Camille Szmaragd; Anthony J Wilson; Simon Carpenter; James L N Wood; Philip S Mellor; Simon Gubbins
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

2.  Evaluation of the immunogenicity of an experimental subunit vaccine that allows differentiation between infected and vaccinated animals against bluetongue virus serotype 8 in cattle.

Authors:  Jenna Anderson; Sara Hägglund; Emmanuel Bréard; Loic Comtet; Karin Lövgren Bengtsson; John Pringle; Stéphan Zientara; Jean Francois Valarcher
Journal:  Clin Vaccine Immunol       Date:  2013-05-29

3.  Evaluation of the humoral immune responses in adult cattle and sheep, 4 and 2.5 years post-vaccination with a bluetongue serotype 8 inactivated vaccine.

Authors:  C A Batten; L Edwards; C A L Oura
Journal:  Vaccine       Date:  2013-06-19       Impact factor: 3.641

4.  A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.

Authors:  Sandro Filipe Nunes; Claude Hamers; Maxime Ratinier; Andrew Shaw; Sylvie Brunet; Pascal Hudelet; Massimo Palmarini
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

5.  Replication-Deficient Particles: New Insights into the Next Generation of Bluetongue Virus Vaccines.

Authors:  Cristina C Celma; Meredith Stewart; Kerstin Wernike; Michael Eschbaumer; Lorenzo Gonzalez-Molleda; Emmanuel Breard; Claudia Schulz; Bernd Hoffmann; Andy Haegeman; Kris De Clercq; Stephan Zientara; Piet A van Rijn; Martin Beer; Polly Roy
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

6.  Attenuation of Bluetongue Virus (BTV) in an in ovo Model Is Related to the Changes of Viral Genetic Diversity of Cell-Culture Passaged BTV.

Authors:  Fabian Z X Lean; Matthew J Neave; John R White; Jean Payne; Teresa Eastwood; Jemma Bergfeld; Antonio Di Rubbo; Vittoria Stevens; Kelly R Davies; Joanne Devlin; David T Williams; John Bingham
Journal:  Viruses       Date:  2019-05-26       Impact factor: 5.048

7.  Reassortment between two serologically unrelated bluetongue virus strains is flexible and can involve any genome segment.

Authors:  Andrew E Shaw; Maxime Ratinier; Sandro Filipe Nunes; Kyriaki Nomikou; Marco Caporale; Matthew Golder; Kathryn Allan; Claude Hamers; Pascal Hudelet; Stéphan Zientara; Emmanuel Breard; Peter Mertens; Massimo Palmarini
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Novel virostatic agents against bluetongue virus.

Authors:  Linlin Gu; Volodymyr Musiienko; Zhijun Bai; Aijian Qin; Stewart W Schneller; Qianjun Li
Journal:  PLoS One       Date:  2012-08-15       Impact factor: 3.240

9.  Protective Efficacy in Sheep of Adenovirus-Vectored Vaccines against Bluetongue Virus Is Associated with Specific T Cell Responses.

Authors:  Verónica Martín; Elena Pascual; Miguel Avia; Lourdes Peña; Félix Valcárcel; Noemí Sevilla
Journal:  PLoS One       Date:  2015-11-30       Impact factor: 3.240

10.  Virus and host factors affecting the clinical outcome of bluetongue virus infection.

Authors:  Marco Caporale; Luigina Di Gialleonorado; Anna Janowicz; Gavin Wilkie; Andrew Shaw; Giovanni Savini; Piet A Van Rijn; Peter Mertens; Mauro Di Ventura; Massimo Palmarini
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.